Common treatments may not be as effective for women as they are for men, mouse model reveals In a nutshell Research reveals ...

Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments ...

FRIDAY, March 28, 2025 (HealthDay News) -- Virtual reality (VR) might be able to provide cancer patients significant pain ...

Latigo Biotherapeutics, Vivace Therapeutics, and Vori Health each announced the recent successful closing of their respective ...

Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for ...

Exploratory phase 1b trial will evaluate safety, tolerability and effect on pain intensity - Topline data readout planned for early 2026 SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics ...

SMi Group Reports: The leading Pain Therapeutics Conference will take place for its 22nd consecutive year on 4th and 5th May 2022 in London, UK to explore novel compounds and treatments for pain ...

and peripheral neuropathic pain. Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with ...

"With its unique mechanistic action, PIPE-791 has the potential to modify the maladaptive changes associated with chronic pain," said Stephen Huhn, Chief Medical Officer, Contineum Therapeutics.